Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: ABSTRACT Introduction Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML). Methods This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients with de novo AML treated between 2014 and 2022 in the French authorization for temporary use (ATU) and post‐ATU program. Results During first induction, most patients (98.1%; 105/107) received GO with other agents, mainly daunorubicin/cytarabine (60.0%; 63/105). After 44.6 months’ median follow‐up (95% CI: 33.8–69.3), 78.6% (88/112) responded; 72.3% (81/112) achieved complete response, 52.2% (24/46) without measurable residual disease. Median (95% CI) event‐free survival (EFS), relapse‐free survival (RFS), and overall survival (OS) were 13.1 months (9.9–17.5), 17.5 months (12.6–35.6), and 49.8 months (21.8–not estimable), respectively. Overall, 46.9% of patients died. Older age predicted shorter OS ( p < 0.001). FLT3‐TKD mutation ( p = 0.013) and adverse cytogenetic classification ( p = 0.015) predicted shorter EFS. ECOG performance status ≥ 2 ( p = 0.005) and adverse cytogenetic classification ( p = 0.001) predicted shorter RFS. Forty‐four patients (38.9%) reported ≥ 1 adverse event of interest; 13.3% were serious and 26.6% treatment‐related; most commonly thrombocytopenia (21.2%). GO was predominantly administered per indication. No new safety signals were reported. Conclusions Results demonstrate real‐world safety and clinical outcomes of GO plus induction therapy for patients with de novo CD33‐positive AML. Trial Registration EU Post Authorization Study (PAS) register number: EUPAS44551
Source: eJHaem
DOI: 10.1002/jha2.70454
Institutions: Centre Hospitalier de Versailles, Hôpital Saint-Louis, Centre Hospitalier Universitaire Amiens-Picardie, Université Sorbonne Paris Nord, Hôpital Avicenne, Hôpital Lyon Sud, Hôpital Simone Veil, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Pfizer (France), Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,860
Funder: Pfizer
OpenAlex ID: W7227177579
